|
業務類別
|
Biotechnology |
|
業務概覽
|
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has otherproducts in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology. |
| 公司地址
| 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108 |
| 電話號碼
| +1 801 994-7383 |
| 傳真號碼
| +1 801 994-7388 |
| 公司網頁
| https://www.lipocine.com |
| 員工數量
| 14 |
| Dr. Mahesh V. Patel, PhD |
Director, President, Chief Executive Officer and Principal Financial Officer |
美元 584.78K |
21/04/2026 |
| Dr. Nachiappan Chidambaram, PhD |
Senior Vice President, Research and Development |
美元 331.20K |
21/04/2026 |
| Ms. Krista Fogarty |
Principal Accounting Officer and Corporate Controller |
美元 275.31K |
21/04/2026 |
|
|
| Dr. Mahesh V. Patel, PhD |
Director, President, Chief Executive Officer and Principal Financial Officer |
21/04/2026 |
| Mr. John W. Higuchi, M.B.A. |
Independent Director |
21/04/2026 |
| Dr. Richard Dana Ono, PhD |
Lead Independent Director and Chairman of the Board |
21/04/2026 |
| Dr. Jill M. Jene, M.B.A.,PhD |
Independent Director |
21/04/2026 |
|
|
|
|
